Sun Pharma sales up 11.8% as India growth offsets U.S. pressure
Sun Pharma reported 11.8% sales growth in Q2 FY27 and kept its annual guidance. Strength in India offset weaker U.S. sales tied to lenalidomide and ILUMYA.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Sun Pharmaceutical Industries reported that its sales for the second quarter of fiscal 2027 rose 11.8%, while adjusted net profit reached INR 31,620 million, according to TradingView. Growth came mainly from India and the innovative medicines segment, both of which expanded over the period.
In the United States, sales came under pressure as revenue from lenalidomide declined and growth of ILUMYA slowed. The company left its FY27 guidance unchanged.
why it matters
For investors, the strong Indian market partly offsets problems in the U.S., where key products are losing sales. Keeping the annual forecast suggests management does not yet see a deterioration, but the market will watch American performance in the coming quarters.
market impact
Sun Pharma shares: India growth against U.S. pressure gives a mixed signal
- Sun Pharma shares mixed — strong India growth offsets weaker U.S. sales from lenalidomide and ILUMYA
tags
instruments
sources
- SUNPHARMA: Sales rose 11.8%; India growth offset U.S. pressure from lenalidomide erosion and slower ILUMYA — TradingView, 30 October 2026 at 14:53 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗